I was hoping you would come on here and tell me he is a well-respected doctor when it comes to HCV clinical trials and HCV research in general. ; ) I Googled and found this entry: http://www.hepccenter.org/dienstag.php .
Suffice to say, I'm not putting any weight into this person's alleged opinion on ACH-1625, but just noting the reference by ACHN management. I care much more about hard clinical results than someone's opinion and, at least to date, the clinical results for ACH-1625 look pretty good IMHO.
Do you have any opinions on what I posted in #msg-47783074 in terms of the size of an up-front milestone that ACHN would likely receive should it enter into a partnership for ACH-1625 prior to the start of Phase 2 trials? Is greater than $40M up-front attainable? $60M? Or do you see $20-30M as the ceiling?
Market Data 
Markets 
AI
